Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | WDR5 | P61964 | 11/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13623213 | 0.90 | MAPT (0.46) | ALDH1A1POLBKMT2ALMNAMAPT | |
| SCHEMBL13623226 | 0.86 | SIRT2 (0.40) | ALDH1A1POLBKMT2AGAAHTT | |
| SCHEMBL4367036 | 0.85 | SIRT2 (0.40) | ALDH1A1POLBKMT2AHTTLMNA | |
| SCHEMBL4367032 | 0.85 | SIRT2 (0.40) | ALDH1A1POLBKMT2AHTTLMNA | |
| SCHEMBL1026372 | 0.84 | LMNA (0.40) | ALDH1A1POLBKMT2ALMNAMAPT | |
| SCHEMBL13622511 | 0.83 | MMP1 (0.45) | ALDH1A1POLBKMT2AGAAHTT | |
| SCHEMBL13622531 | 0.82 | MEN1 (0.47) | ALDH1A1POLBKMT2AHTTLMNA | |
| SCHEMBL1025393 | 0.81 | MEN1 (0.43) | ALDH1A1KMT2AHTTLMNAMAPT | |
| SCHEMBL1028055 | 0.79 | MMP1 (0.37) | ALDH1A1POLBKMT2AWDR5 | |
| SCHEMBL1028056 | 0.79 | MMP1 (0.37) | ALDH1A1POLBKMT2AWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | ALDH1A1 2511/4885POLB 2346/4885KMT2A 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.